Hormonal
GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) significantly suppress hunger, reduce 'food noise' (intrusive thoughts about food), and increase early satiety during the dynamic weight loss phase, leading to reduced portion sizes and cravings.
When starting GLP-1 medications, expect a significant reduction in hunger and intrusive thoughts about food ('food noise'). This is a biological effect, not just willpower. You may feel full faster and eat smaller portions. This effect is strongest in the first few months (dynamic phase). If you stop the medication, hunger and food noise typically return, so long-term adherence is often necessary for sustained benefits.
The dynamic phase reported profound appetite suppression, early fullness, reduced ‘food noise’ with diminished cravings and smaller portion size.
Why this rating
Qualitative study with small sample size (n=31), though findings align with quantitative trials.
Source
Changes in Eating Behaviour During Treatment With Obesity Medications
Ming Chuen Chong et al. · Clinical Obesity · 2025
DOI 10.1111/cob.70065
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →